Deals Of The Week Road Tests Biopharma’s Options
Executive Summary
The industry has pulled back on experimentation with option-to-license deals; results have been mediocre and biotechs, no longer as cash-strapped as they were in 2009, when option deals peaked, have other … options. Plus deals by Roche, Endo, Pfizer, GSK and others.
You may also be interested in...
Pfizer’s CTI Shows Tangible Signs Of Progress In Its Junior Year
Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.
Patient-Centric: Evotec’s CSO Explains R&D Strategy
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk, Evotec Link Around Chronic Kidney Disease
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: